Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx.

ABSTRACT:

Unlabelled

This observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.

SUBMITTER: Youn CG 

PROVIDER: S-EPMC11661688 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature